Bank of New York Mellon Corp acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 224,176 shares of the biopharmaceutical company's stock, valued at approximately $8,342,000. Bank of New York Mellon Corp owned 0.29% of Celldex Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in CLDX. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics during the 3rd quarter worth approximately $42,000. Russell Investments Group Ltd. raised its stake in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Celldex Therapeutics in the third quarter valued at $63,000. Kestra Advisory Services LLC purchased a new position in Celldex Therapeutics in the fourth quarter valued at $98,000. Finally, Advisory Services Network LLC purchased a new position in Celldex Therapeutics in the third quarter valued at $139,000.
Analyst Upgrades and Downgrades
CLDX has been the topic of a number of recent research reports. Guggenheim upped their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Monday, July 20th. UBS Group lifted their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, June 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Celldex Therapeutics in a report on Friday, July 17th. Wells Fargo & Company increased their price objective on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Finally, Barclays raised their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an "overweight" rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Celldex Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $56.08.
Get Our Latest Stock Analysis on CLDX
Celldex Therapeutics Stock Performance
CLDX opened at $39.37 on Friday. Celldex Therapeutics, Inc. has a one year low of $22.10 and a one year high of $45.14. The company has a market cap of $3.09 billion, a P/E ratio of -9.05 and a beta of 0.84. The business's 50-day simple moving average is $38.98 and its 200-day simple moving average is $33.76.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. As a group, analysts predict that Celldex Therapeutics, Inc. will post -4.13 earnings per share for the current fiscal year.
About Celldex Therapeutics
(
Free Report)
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company's research platforms leverage novel antibody and vaccine technologies designed to engage the patient's immune system, with a particular emphasis on oncology and neurologic indications. Celldex's pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.
Among Celldex's lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.
Featured Articles
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
